| anti-PD-(L)1 | pembrolizumab based treatment |
| pembrolizumab based treatment | pembrolizumab alone | pembrolizumab plus lenvatinib |
| mHCC - (neo)adjuvant (NA) | | | |
| mHCC - 1st line (L1) 4 | | | |
| mHCC - 2nd line (L2) 2 | | | |
Comparator:
vs lenvatinib; vs placebo;
Risk of bias:
low;
some concerns;
high;
NA;